CHEcking Diagnostic Differential Ability of Real Baseline Variables and Frailty Scores in Tolerance of Anti-Cancer Systemic Therapy in OldEr Patients (CHEDDAR-TOASTIE)
Models lack sufficiently robust results for clinical utility. However, a high NPV in predicting no toxicity could help identify lower-risk patients who may not require dose reductions, potentially improving overall outcomes.
Authors
- Helen Clare Dearden (ORCID: https://orcid.org/0000-0003-3365-998X)
- Kieran Zucker (ORCID: https://orcid.org/0000-0003-4385-3153)
- I Mahmood
- Helen Ng (ORCID: https://orcid.org/0000-0002-7465-2090)
- Mark Baxter (ORCID: https://orcid.org/0000-0002-5773-8650)
- Francis Aggrey
Institutions
- University of Leeds (GB)
- University of Dundee (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- NHS Tayside (GB)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3390/cancers17203303
- Primary Topic
- Frailty in Older Adults
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Astellas Pharma
- Servier
- Ipsen